Help getting access to lambrolizumab

Posted By
7/30/2014 3:44pm
Replies: 6



I'm not oncologist, just a GP and I wish I can help one of my patient and friend here in Europe to access this treatment (or the other anti-PD-1 antibody) ...

Is there a way to get it under "compationate use" she will pay for it , is she can afford...

Looking for any assistance in this way,


thank you for this usefull board

Sorry I can't answer you question, but you might want to also check with Catherine Poole at MIF (  That board tends to have a bit more of an international scope.



Stage 4  (TXN2cM1b)-- 2008 WLE, SNB, LND, HD-INF, GM-CSF, (intransits) 2013 IPI, (intransits) 2014 PEMBRO, (intransits and lung met) 2016 VATs

In Spain is possible to get it under compassionate use, after ipi fail or braf inh.

Where are you from?

Take a look at the post from Tim of the MRA dated 7/10 /2014. He talks about the expanded access to the Ipilimumab and Nivolumab combination by Bristol Myer Squibb. Also the name has changed from MK-3475 to Lambrolizumab to Pembrolizumab. Dr. Antoni Ribas at UCLA is involved with the research on this drug but I am not sure where or how you would get access. I know that Nivolumab has become available in Japan by Ono Pharmaceutical Co, where they call it Opdivo. Hope this helps!!! Ed

Anonymous - (7/30/2014 - 5:45pm)

thank you very much all three, I didn't expect so quick response!

I'm in france and indeed my prescription as GP may not be enough to convince a lab in my opinion ..

That's also often I have patients with NSCLC and I'm in the same situation, I see some additional possibilities abroad and can't access them 

here no oncologist will take the responsability to prescribe a drug that has not approbation in the country ... they are so afraid to get troubles

If anyone has a more precise suggestion it create en temporary email to take contact no to leave my identity on this board ... 

feel free to leave a message at , sorry not to give my true email , I don't want to lose my med board registration...

I think you need to transfer your patient to Villejuif to the Institut  Gustave Roussy. they are as far as I know the only French site where the Merck EAP for Pembrolizumab is open. So they will get access for your friend.
If he / she is BRAF+ he has to have failed this and he has to habe failed Ipilimumab. There are some more criteria that the people at the IGR wil know.
hope this helps!

Anti-pd1 therapies have been recently approved in Japan. Perhaps your friend can get a referral to a Japanese Melanoma  Oncologist there who can prescribe treatment and pay out of pocket.  Worth a look.